Breaking News Instant updates and real-time market news.

TROV

Trovagene

$0.81

-0.0216 (-2.61%)

, AZN

AstraZeneca

$34.17

-0.65 (-1.87%)

08:04
06/12/17
06/12
08:04
06/12/17
08:04

Trovagene enters agreement with AstraZeneca in prospective biomarker study

Trovagene (TROV) announced it has entered into an agreement with AstraZeneca (AZN) to provide Trovera urine ctDNA biomarker test and services. The Trovera EGFR urine liquid biopsy test will initially be used in an open label prospective biomarker study evaluating whether the combined use of noninvasive testing is as effective as tissue testing in identifying epidermal growth factor receptor T790M mutation status.

TROV

Trovagene

$0.81

-0.0216 (-2.61%)

AZN

AstraZeneca

$34.17

-0.65 (-1.87%)

  • 15

    Jun

  • 26

    Jun

TROV Trovagene
$0.81

-0.0216 (-2.61%)

04/12/17
MAXM
04/12/17
UPGRADE
Target $4
MAXM
Buy
Maxim upgrades Trovagene back to Buy with $4 target
Maxim analyst Jason McCarthy upgraded Trovagene to Buy intraday after downgrading the stock to Hold on March 16. In-licensing a small molecule oncology drug from Nerviano Medical Sciences marks a new chapter for the company in precision cancer therapeutics, McCarthy tells investors in a research note. The analyst set a $4 price target for the shares. Trovagene in midday trading is up 15% to 87c.
04/12/17
MAXM
04/12/17
UPGRADE
Target $4
MAXM
Buy
Trovagene upgraded to Buy from Hold at Maxim
Maxim analyst Jason Kolbert upgraded Trovagene to Buy with a $4 price target. The analyst downgraded the shares to Hold on Marhc 16.
03/16/17
MAXM
03/16/17
DOWNGRADE
MAXM
Hold
Trovagene downgraded to Hold from Buy at Maxim
Maxim analyst Jason Kolbert downgraded Trovagene to Hold from Buy, saying he will need to re-evaluate the company given its newly announced strategic direction to focus on developing diagnostic-based therapeutics. Piper Jaffray analyst William Quirk also downgraded Trovagene to Underweight this morning.
03/16/17
PIPR
03/16/17
DOWNGRADE
Target $0.5
PIPR
Underweight
Trovagene downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray analyst William Quirk downgraded Trovagene to Underweight citing an uncertain commercial strategy amid the company's shifts from liquid biopsy to collection devices to therapeutics. He cut his price target for the shares to 50c from $1.70 following Trovagene's Q4 results.
AZN AstraZeneca
$34.17

-0.65 (-1.87%)

06/06/17
WELS
06/06/17
NO CHANGE
WELS
Amazon may be the next threat to drug pricing, says Wells Fargo
After CNBC recently reported that Amazon (AMZN) is considering going into the prescription pharmacy business in the U.S., Wells Fargo surveyed nearly 2,900 U.S. adults and found that 54% of those polled said they would use or would probably use "Amazon Pharmacy." While the e-commerce giant has not confirmed its U.S. pharmacy interest, if it did enter the market analyst David Maris believes it could see fast adoption and "usher in a new age of price transparency." Maris also wonders if pharmacy "may be just the beginning" and if Amazon eyes the "even larger prize" of fully integrated digital healthcare. Publicly traded large-cap pharmaceuticals companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded retail pharmacy operators include CVS Health (CVS), Walgreens (WBA), Fred's (FRED) and Rite Aid (RAD).
06/05/17
PIPR
06/05/17
NO CHANGE
PIPR
Piper views AstraZeneca, J&J as ASCO standouts
The standouts at ASCO over the weekend were the "compelling results" presented on Johnson & Johnson's (JNJ) Zytiga from the Latitude study in prostate cancer and AstraZeneca's (AZN) Lynparza in the OlympiAD trial in BRCA mutant breast cancer, Piper Jaffray analyst Richard Purkiss tells investors in a research note. In lung cancer, Merck's (MRK) updated data in KN021G "appears more promising" than Bristol-Myers' (BMY) updated data in CM012, the analyst adds. Purkiss believes, however, that relative to recent ASCOs, the data "so far in totality is underwhelming."
06/01/17
RHCO
06/01/17
NO CHANGE
RHCO
SunTrust sees $240/share takeout price for Tesaro
After the Wall Street Journal reported yesterday that Tesaro (TSRO) is exploring a sale, albeit with "modest" interest, SunTrust analyst Peter Lawson says his analysis suggests a $240 per share takeout price for the company. Tesaro closed yesterday up $5.88, or 4%, to $149.31. Acquisitions in the PARP inhibitor space are more likely to happen after Clovis Oncology's (CLVS) ARIEL 3 data at the end of June, as the readout will provide a more apples-to-apples comparison to Tesaro and AstraZeneca (AZN), Lawson tells investors in a research note. His "bull case" points to a $286 per share price for Tesaro and $92 per share price for Clovis. Lawson has Buy ratings on both names. JPMorgan's Cory Kasimov this morning said he likes the setup for Clovis shares into the late June data announcement.
05/17/17
JPMS
05/17/17
UPGRADE
Target $72
JPMS
Overweight
Clovis upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Cory Kasimov upgraded Clovis Oncology (CLVS) to Overweight and raised his price target for the shares to $72 from $58. The stock closed yesterday up 2%, or $1.05, to $49.56. The shares are down 35% over the last two months for "no clear fundamental reason," Kasimov tells investors in a research note. The analyst is "increasingly comfortable" recommending Clovis ahead of its Phase 3 study evaluating Rubraca in maintenance ovarian cancer now that more PARP class data has emerged. He has not seen "convincing evidence" that there is a clear efficacy difference between Clovis' rucaparib, Tesaro's (TSRO) niraparib and AstraZeneca's (AZN) olaparib.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

12:17
01/19/18
01/19
12:17
01/19/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASFI

Asta Funding

$7.35

0.05 (0.68%)

12:16
01/19/18
01/19
12:16
01/19/18
12:16
Hot Stocks
Asta Funding receives Nasdaq non-compliance letter »

Asta Funding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$14.49

1.28 (9.69%)

12:16
01/19/18
01/19
12:16
01/19/18
12:16
Hot Stocks
NuCana to resume trading at 12:30 pm ET »

NuCana is scheduled to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:16
01/19/18
01/19
12:16
01/19/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.15

-0.35 (-2.26%)

12:15
01/19/18
01/19
12:15
01/19/18
12:15
Hot Stocks
Breaking Hot Stocks news story on Momenta »

Momenta jumps 14%, halted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$14.27

0.18 (1.28%)

12:15
01/19/18
01/19
12:15
01/19/18
12:15
Options
MiMedx put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.15

-0.35 (-2.26%)

12:14
01/19/18
01/19
12:14
01/19/18
12:14
Periodicals
Breaking Periodicals news story on Momenta »

Momenta weighing options,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNTA

Momenta

$15.15

-0.35 (-2.26%)

12:14
01/19/18
01/19
12:14
01/19/18
12:14
Hot Stocks
Breaking Hot Stocks news story on Momenta »

Momenta trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRG

NRG Energy

$26.50

-0.31 (-1.16%)

12:05
01/19/18
01/19
12:05
01/19/18
12:05
Options
NRG Energy call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMNB

American National Bankshares

$39.10

-0.8 (-2.01%)

12:03
01/19/18
01/19
12:03
01/19/18
12:03
Hot Stocks
American National Bankshares announces 300,000 share repurchase program »

American National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBIB

Porter Bancorp

$13.76

0.06 (0.44%)

12:02
01/19/18
01/19
12:02
01/19/18
12:02
Hot Stocks
PBI Bank changes name to Limestone Bank »

In the first weeks of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$14.49

1.28 (9.69%)

12:01
01/19/18
01/19
12:01
01/19/18
12:01
Hot Stocks
NuCana reports 'promising' clinical data on Acelarin »

NuCana announced interim…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NCNA

NuCana

$14.49

1.28 (9.69%)

11:55
01/19/18
01/19
11:55
01/19/18
11:55
Hot Stocks
Breaking Hot Stocks news story on NuCana »

NuCana PLC (ADS) trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYL

Mylan

$46.51

-0.27 (-0.58%)

11:55
01/19/18
01/19
11:55
01/19/18
11:55
Options
Mylan put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

  • 08

    Mar

BTC

Bitcoin

, BAC

Bank of America

$31.55

0.07 (0.22%)

11:52
01/19/18
01/19
11:52
01/19/18
11:52
Hot Stocks
The Intersection: Crypto and Wall Street This Week »

As bitcoin, ethereum and…

BTC

Bitcoin

BAC

Bank of America

$31.55

0.07 (0.22%)

MS

Morgan Stanley

$56.67

0.83 (1.49%)

GS

Goldman Sachs

$252.15

1.18 (0.47%)

V

Visa

$122.10

-1.015 (-0.82%)

AMD

AMD

$12.47

0.29 (2.38%)

NVDA

Nvidia

$224.44

-0.28 (-0.12%)

OSTK

Overstock.com

$71.25

-4.4 (-5.82%)

DPW

DPW Holdings

$2.30

-0.05 (-2.13%)

LBCC

Long Blockchain Corp.

$4.51

0.3 (7.13%)

KODK

Kodak

$10.05

-0.1 (-0.99%)

SSC

Seven Stars Cloud Group

$4.53

-0.1 (-2.16%)

RIOT

Riot Blockchain

$19.80

2.04 (11.49%)

LFIN

Longfin

$44.69

6.09 (15.78%)

TEUM

Pareteum

$2.37

0.01 (0.42%)

SRAX

Social Reality

$4.96

0.17 (3.55%)

GBTC

Bitcoin Investment Trust

$1,857.00

221 (13.51%)

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 30

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 15

    Feb

AOS

A.O. Smith

$66.32

0.41 (0.62%)

11:51
01/19/18
01/19
11:51
01/19/18
11:51
Hot Stocks
A.O. Smith announces 29% boost in dividend »

Directors of A. O. Smith…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Jan

TYME

Tyme Technologies

$6.15

-0.85 (-12.14%)

11:50
01/19/18
01/19
11:50
01/19/18
11:50
Hot Stocks
Tyme Technologies reports 'positive' efficacy data for SM-88 »

Tyme Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

AMOT

Allied Motion

$35.44

-0.06 (-0.17%)

11:48
01/19/18
01/19
11:48
01/19/18
11:48
Hot Stocks
Allied Motion acquires original equipment steering business from Maval »

Allied Motion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$220.33

2.83 (1.30%)

11:40
01/19/18
01/19
11:40
01/19/18
11:40
Technical Analysis
Technical Earnings Preview: Netflix near life highs before earnings news »

Shares are trading near…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

FXI

iShares China Large-Cap ETF

$51.64

0.565 (1.11%)

11:40
01/19/18
01/19
11:40
01/19/18
11:40
Options
Defensive option play in iShares China Fund as the rally continues »

Defensive option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVI

Activision Blizzard

$69.80

-0.56 (-0.80%)

, TTWO

Take-Two

$117.27

1.18 (1.02%)

11:33
01/19/18
01/19
11:33
01/19/18
11:33
Periodicals
NPD says 'Call of Duty: WWII' top selling game in U.S. in 2017, VentureBeat says »

NPD Group said that…

ATVI

Activision Blizzard

$69.80

-0.56 (-0.80%)

TTWO

Take-Two

$117.27

1.18 (1.02%)

EA

Electronic Arts

$115.28

2.14 (1.89%)

NTDOY

Nintendo

$52.69

1.155 (2.24%)

UBSFY

Ubisoft

$16.67

-0.31 (-1.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 30

    Jan

  • 08

    Feb

  • 21

    Feb

  • 22

    Feb

  • 07

    Dec

BK

BNY Mellon

$55.89

0.535 (0.97%)

11:31
01/19/18
01/19
11:31
01/19/18
11:31
Hot Stocks
Street Fight: JPMorgan cuts BNY Mellon on tax reform moves, MS upgrades »

Shares of Bank of New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

ATVI

Activision Blizzard

$69.80

-0.56 (-0.80%)

, EA

Electronic Arts

$115.28

2.14 (1.89%)

11:30
01/19/18
01/19
11:30
01/19/18
11:30
Periodicals
Activision's 'Call of Duty: WWII' best selling game in Dec, VentureBeat says »

The NPD Group said that…

ATVI

Activision Blizzard

$69.80

-0.56 (-0.80%)

EA

Electronic Arts

$115.28

2.14 (1.89%)

NTDOY

Nintendo

$52.69

1.155 (2.24%)

TTWO

Take-Two

$117.27

1.18 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 30

    Jan

  • 08

    Feb

  • 21

    Feb

  • 22

    Feb

  • 07

    Dec

TEVA

Teva

$20.90

0.185 (0.89%)

, MYL

Mylan

$46.51

-0.27 (-0.58%)

11:30
01/19/18
01/19
11:30
01/19/18
11:30
Periodicals
DOJ official says U.S. may sue generic drugmakers, Bloomberg reports »

Bloomberg cites the…

TEVA

Teva

$20.90

0.185 (0.89%)

MYL

Mylan

$46.51

-0.27 (-0.58%)

ENDP

Endo

$7.35

-0.34 (-4.42%)

LCI

Lannett

$24.55

0.9 (3.81%)

PRGO

Perrigo

$91.03

-0.66 (-0.72%)

AKRX

Akorn

$33.06

-0.09 (-0.27%)

TARO

Taro Pharmaceutical

$104.99

-2.275 (-2.12%)

IPXL

Impax

$20.55

0.15 (0.74%)

NVS

Novartis

$86.47

0.06 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 08

    Feb

  • 16

    Feb

  • 01

    Mar

  • 02

    Mar

  • 08

    Mar

  • 23

    Apr

  • 17

    May

  • 21

    Jul

PTCT

PTC Therapeutics

$20.93

-1.02 (-4.65%)

11:30
01/19/18
01/19
11:30
01/19/18
11:30
Options
Bullish flow in PTC Therapeutics as shares spike »

Bullish flow in PTC…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.